Search Results

Merrimack Pharmaceuticals, Inc. announced that the stockholders at a Special Meeting held overwhelmingly approved adopting a Plan of Dissolution.

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced that the Board of Directors intends to declare a liquidating cash dividend in the amount of $15.10 per share, if stockholder approval of the Plan of Dissolution is obtained at the Special Meeting of Stockholders held on May 10, 2024.

Merrimack Pharmaceuticals, Inc. announced that it has filed notice with NASDAQ of the Company’s intent to delist its securities from NASDAQ, subject to receipt of stockholder approval of the Plan of Dissolution at the Special Meeting of Stockholders of Merrimack scheduled to be held on Friday, May 10, 2024.

Merrimack Pharmaceuticals, Inc. announced its full year 2023 financial results for the period ended December 31, 2023.

Merrimack Pharmaceuticals, Inc. announced that it has received a $225 million payment which was due from Ipsen, S.A. as a result of its receipt of approval from the U.S. Food and Drug Administration, or FDA, to market ONIVYDE as a first-line treatment of metastatic adenocarcinoma on the pancreas.

Merrimack Pharmaceuticals, Inc. announced its third quarter 2023 financial results for the period ended September 30, 2023.

Merrimack Pharmaceuticals, Inc. reported that Ipsen, SA issued a press release announcing the U.S. Food and Drug Administration has approved the supplemental new drug application for Onivyde® plus 5 fluorouracil/leucovorin and oxaliplatin as a first-line treatment for people living with metastatic pancreatic ductal adenocarcinoma.

Merrimack Pharmaceuticals, Inc. announced its second quarter 2023 financial results for the period ended June 30, 2023.

Merrimack Pharmaceuticals, Inc. announced its first quarter 2023 financial results for the period ended March 31, 2023.

Verrica Pharmaceuticals Inc. today announced the settlement of litigation with Dormer Laboratories, Inc. (“Dormer Labs”).